Glucagon-like peptide-1 therapies remain a major cost driver of employer-sponsored drug plans and will further contribute to costs as they become approved for uses beyond managing obesity and diabetes, according to a new report by Alberta Blue Cross. The report, which reviewed more than 440 new drug and supplemental submissions made to Health Canada in […]
As dermatological treatments move up the ranking of conditions with the highest paid drug claims, they’ve become increasingly significant for private drug plan sponsors, according to Frances Lehun, a pharmacist with pharmaceutical expertise in high-cost drug management at Beneva. During a session at the 2025 Face to Face Drug Plan Management Forum, she said this […]